These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 36249274)

  • 1. AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma.
    Strecker MI; Wlotzka K; Strassheimer F; Roller B; Ludmirski G; König S; Röder J; Opitz C; Alekseeva T; Reul J; Sevenich L; Tonn T; Wels WS; Steinbach JP; Buchholz CJ; Burger MC
    Oncoimmunology; 2022; 11(1):2127508. PubMed ID: 36249274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy.
    Xia W; Chen J; Hou W; Chen J; Xiong Y; Li H; Qi X; Xu H; Xie Z; Li M; Zhang X; Li J
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
    Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
    Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells.
    Bajor M; Graczyk-Jarzynka A; Marhelava K; Burdzinska A; Muchowicz A; Goral A; Zhylko A; Soroczynska K; Retecki K; Krawczyk M; Klopotowska M; Pilch Z; Paczek L; Malmberg KJ; Wälchli S; Winiarska M; Zagozdzon R
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
    Mei S; Peng S; Vong EG; Zhan J
    Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
    Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
    Front Immunol; 2019; 10():2683. PubMed ID: 31798595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
    Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors.
    Reul J; Frisch J; Engeland CE; Thalheimer FB; Hartmann J; Ungerechts G; Buchholz CJ
    Front Oncol; 2019; 9():52. PubMed ID: 30838171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.
    Huang BY; Zhan YP; Zong WJ; Yu CJ; Li JF; Qu YM; Han S
    PLoS One; 2015; 10(8):e0134715. PubMed ID: 26266810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.
    Rosewell Shaw A; Porter CE; Watanabe N; Tanoue K; Sikora A; Gottschalk S; Brenner MK; Suzuki M
    Mol Ther; 2017 Nov; 25(11):2440-2451. PubMed ID: 28974431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
    Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant radiotherapy in ER
    Bruss C; Albert V; Seitz S; Blaimer S; Kellner K; Pohl F; Ortmann O; Brockhoff G; Wege AK
    Front Immunol; 2024; 15():1355130. PubMed ID: 38742103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography.
    Shalaby N; Xia Y; Kelly JJ; Sanchez-Pupo R; Martinez F; Fox MS; Thiessen JD; Hicks JW; Scholl TJ; Ronald JA
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3176-3190. PubMed ID: 38722382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics.
    Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R
    Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-articular delivery of AAV vectors encoding PD-L1 attenuates joint inflammation and tissue damage in a mouse model of rheumatoid arthritis.
    Li W; Sun J; Feng SL; Wang F; Miao MZ; Wu EY; Wallet S; Loeser R; Li C
    Front Immunol; 2023; 14():1116084. PubMed ID: 36936967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.